Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Higgins

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
BMJ Open Respiratory Research|May 25, 2023
Registry-based study in people with cystic fibrosis and an <i>R117H</i> variant treated with ivacaftorMark Higgins, Thalia Farietta, Daniel Campbell, et al.
CASE (Philadelphia, Pa.)|March 25, 2024
Transseptal Mitral Valve-in-Valve-in-ValveBlanaid Canavan, Mark Higgins, Dale J Murdoch, et al.
Current Medical Research and Opinion|February 6, 2009
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterolOlivier Bauwens, Vincent Ninane, Boudewijn Van de Maele, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|June 23, 2010
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trialMotokazu Kato, Hironi Makita, Koji Uemura, et al.
Pulmonary Therapy|September 23, 2020
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive MutationsJoseph M Pilewski, Kris De Boeck, Jerry A Nick, et al.
Current Medical Research and Opinion|May 16, 2013
Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trialIvanka Galeva, Michael W Konstan, Mark Higgins, et al.
Respiratory Medicine|July 13, 2010
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterolNaruhiko Sugihara, Shigeto Kanada, Michiko Haida, et al.
Bone & Joint Research|July 16, 2025
The impact of cementing technique in polished taper fit hip stems : a modelling analysis of implant-cement interfaceBernard H van Duren, Mohamad Taufiqurrakhman, Alison Jones, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2008
Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety studyWilliam H Yang, Jean Benoit Martinot, Petr Pohunek, et al.
Pulmonary Pharmacology & Therapeutics|July 13, 2010
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover studyCraig Laforce, Joseph Aumann, Luis de Teresa Parreño, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
BMJ Open Respiratory Research|May 25, 2023
Registry-based study in people with cystic fibrosis and an <i>R117H</i> variant treated with ivacaftorMark Higgins, Thalia Farietta, Daniel Campbell, et al.
CASE (Philadelphia, Pa.)|March 25, 2024
Transseptal Mitral Valve-in-Valve-in-ValveBlanaid Canavan, Mark Higgins, Dale J Murdoch, et al.
Current Medical Research and Opinion|February 6, 2009
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterolOlivier Bauwens, Vincent Ninane, Boudewijn Van de Maele, et al.
Allergology International : Official Journal of the Japanese Society of Allergology|June 23, 2010
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trialMotokazu Kato, Hironi Makita, Koji Uemura, et al.
Pulmonary Therapy|September 23, 2020
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive MutationsJoseph M Pilewski, Kris De Boeck, Jerry A Nick, et al.
Current Medical Research and Opinion|May 16, 2013
Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trialIvanka Galeva, Michael W Konstan, Mark Higgins, et al.
Respiratory Medicine|July 13, 2010
24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: a comparison with placebo and salmeterolNaruhiko Sugihara, Shigeto Kanada, Michiko Haida, et al.
Bone & Joint Research|July 16, 2025
The impact of cementing technique in polished taper fit hip stems : a modelling analysis of implant-cement interfaceBernard H van Duren, Mohamad Taufiqurrakhman, Alison Jones, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2008
Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety studyWilliam H Yang, Jean Benoit Martinot, Petr Pohunek, et al.
Pulmonary Pharmacology & Therapeutics|July 13, 2010
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover studyCraig Laforce, Joseph Aumann, Luis de Teresa Parreño, et al.
Pageof 6